CTI BioPharma (CTIC) has been under a strong bear grip, hence the stock is down -0.89% when compared to the S&P 500 in the past 4 weeks. However, in the near-term, buying emerged at lower levels and the stock has outperformed the S&P 500 by 5.7% in the past 1 week. The stock has continued its bullish performance both in the near-term and the medium-term, as the stock is up 6.15% in the last 1 week, and is up 1.57% in the past 4 weeks. Buying continues as the stock moves higher, suggesting a strong appetite for the stock.
CTI BioPharma (NASDAQ:CTIC): The stock opened at $0.37 on Friday but the bulls could not build on the opening and the stock topped out at $0.37 for the day. The stock traded down to $0.35 during the day, due to lack of any buying support eventually closed down at $0.36 with a loss of -4.15% for the day. The stock had closed at $0.37 on the previous day. The total traded volume was 811,382 shares.
The stock has recorded a 20-day Moving Average of 0.31% and the 50-Day Moving Average is 7.32%. CTI BioPharma Corp. has dropped 20.73% during the last 3-month period . Year-to-Date the stock performance stands at -71.09%.
CTI BioPharma (CTIC) : The highest level CTI BioPharma (CTIC) is projected to reach is $5 for the short term and the lowest estimate is at $1. The consolidated price target from 2 rating analysts who initiate coverage on the stock is $2.88 and the possibility the share price can swing is $3.01.
CTI BioPharma Corp. (CTI), formerly Cell Therapeutics, Inc., is a biopharmaceutical company focused on the acquisition, development and commercialization of targeted therapies covering a spectrum of blood-related cancers that offer a benefit to patients and healthcare providers. The Company is focused on commercializing PIXUVRI (pixantrone), or PIXUVRI, in the European Union, for the treatment of adult patients with multiply relapsed or refractory aggressive B-cell non-Hodgkin lymphoma (NHL), and conducting a Phase III clinical trial program of pacritinib for the treatment of adult patients with myelofibrosis to support regulatory submission for approval in the United States and Europe. It is also engaged in evaluating pacritinib in earlier clinical trials as treatment for other blood-related cancers. Its development product candidates include tosedostat and Opaxio.